US equities · SEC fundamentals

ABBOTT LABORATORIES

ABT · CIK 0000001800 · Pharmaceutical Preparations

Source: SEC EDGAR/XBRL

Revenue

USD

44.3B USD

Period data
PeriodValue
FY 202143.1B USD
FY 202243.7B USD
FY 202340.1B USD
FY 202442B USD
FY 202544.3B USD

Operating income

USD

8.1B USD

Period data
PeriodValue
FY 20218.4B USD
FY 20228.4B USD
FY 20236.5B USD
FY 20246.8B USD
FY 20258.1B USD

Net income

USD

6.5B USD

Period data
PeriodValue
FY 20217.1B USD
FY 20226.9B USD
FY 20235.7B USD
FY 202413.4B USD
FY 20256.5B USD

Total assets

USD

86.7B USD

Period data
PeriodValue
FY 202175.2B USD
FY 202274.4B USD
FY 202373.2B USD
FY 202481.4B USD
FY 202586.7B USD

Equity

USD

52.1B USD

Period data
PeriodValue
FY 202135.8B USD
FY 202236.7B USD
FY 202338.6B USD
FY 202447.7B USD
FY 202552.1B USD

Operating cash flow

USD

9.6B USD

Period data
PeriodValue
FY 202110.5B USD
FY 20229.6B USD
FY 20237.3B USD
FY 20248.6B USD
FY 20259.6B USD

Revenue growth

%

5.7%

Period data
PeriodValue
FY 202124.5%
FY 20221.3%
FY 2023-8.1%
FY 20244.6%
FY 20255.7%

Operating income growth

%

18%

Period data
PeriodValue
FY 202157.3%
FY 2022-0.7%
FY 2023-22.5%
FY 20245.4%
FY 202518%

Net income growth

%

-51.3%

Period data
PeriodValue
FY 202157.3%
FY 2022-2%
FY 2023-17.5%
FY 2024134.2%
FY 2025-51.3%

Operating margin

%

18.2%

Period data
PeriodValue
FY 202119.6%
FY 202219.2%
FY 202316.2%
FY 202416.3%
FY 202518.2%

Net margin

%

14.7%

Period data
PeriodValue
FY 202116.4%
FY 202215.9%
FY 202314.3%
FY 202431.9%
FY 202514.7%

Return on assets

%

7.8%

Period data
PeriodValue
FY 20219.6%
FY 20229.3%
FY 20237.8%
FY 202417.3%
FY 20257.8%

Debt/Equity

x

No applicable data available

Period data
PeriodValue
FY 2021N/A
FY 2022N/A
FY 2023N/A
FY 2024N/A
FY 2025N/A